These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23072608)

  • 1. Letter: sorafenib in portal hypertension.
    Procopet B; Bureau C; Peron JM
    Aliment Pharmacol Ther; 2012 Nov; 36(10):994; author reply 994-5. PubMed ID: 23072608
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
    Pinter M; Sieghart W; Reiberger T; Rohr-Udilova N; Ferlitsch A; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2012 Jan; 35(1):83-91. PubMed ID: 22032637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
    Coriat R; Gouya H; Mir O; Ropert S; Vignaux O; Chaussade S; Sogni P; Pol S; Blanchet B; Legmann P; Goldwasser F
    PLoS One; 2011 Feb; 6(2):e16978. PubMed ID: 21340026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract]   [Full Text] [Related]  

  • 6. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX; Clark JW
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib in advanced hepatocellular carcinoma.
    Copur MS
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 9. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
    Mejias M; Garcia-Pras E; Tiani C; Miquel R; Bosch J; Fernandez M
    Hepatology; 2009 Apr; 49(4):1245-56. PubMed ID: 19137587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in liver cancer--just the beginning.
    Roberts LR
    N Engl J Med; 2008 Jul; 359(4):420-2. PubMed ID: 18650519
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy: sorafenib.
    Finn RS
    Hepatology; 2010 May; 51(5):1843-9. PubMed ID: 20432260
    [No Abstract]   [Full Text] [Related]  

  • 14. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
    Cabibbo G; Rolle E; De Giorgio M; Genco C; Pressiani T; Spada F; Sacco R;
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapy: not just for cancer anymore?
    Shah VH; Bruix J
    Hepatology; 2009 Apr; 49(4):1066-8. PubMed ID: 19330868
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 18. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
    Peck-Radosavljevic M; Greten TF; Lammer J; Rosmorduc O; Sangro B; Santoro A; Bolondi L
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):391-8. PubMed ID: 19940784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sorafenib in advanced hepatocellular carcinoma].
    Sauerbruch T; Gonzalez-Carmona AM; Nitschmann S
    Internist (Berl); 2009 Nov; 50(11):1290-2. PubMed ID: 19771405
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hepatocellular carcinoma].
    Yamashita T; Arai K; Kaneko S
    Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.